Physician profile
John E Streit
NPI 1538262928
$6,433.63
in general payments reported to CMS, 2019-2025
13 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $601 · 2021: $800 · 2022: $941 · 2023: $1,014 · 2024: $1,084 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,875.14 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $1,113.02 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $1,096.39 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $601.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $403.87 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $348.97 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $236.16 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $201.42 | 2021-2023 | Tobradex St |
| Tarsus Pharmaceuticals, INC. | $151.46 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $147.93 | 2019 | |
| Aerie Pharmaceuticals, INC. | $113.13 | 2019-2021 | |
| Alcon Vision LLC | $92.11 | 2022-2025 | Rocklatan, Eysuvis |
| Dompe US, INC. | $52.14 | 2024-2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Streit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.